Regen BioPharma (Regen BioPharma) Days Payable : 0.00 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Regen BioPharma Days Payable?

Regen BioPharma's average Accounts Payable for the three months ended in Mar. 2024 was $0.04 Mil. Regen BioPharma's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil.

The historical rank and industry rank for Regen BioPharma's Days Payable or its related term are showing as below:

RGBP's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 146.16
* Ranked among companies with meaningful Days Payable only.

Regen BioPharma's Days Payable stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00). stayed the same

Regen BioPharma Days Payable Historical Data

The historical data trend for Regen BioPharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma Days Payable Chart

Regen BioPharma Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Days Payable

Get a 7-Day Free Trial

Regen BioPharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Regen BioPharma's Days Payable

For the Biotechnology subindustry, Regen BioPharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regen BioPharma's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's Days Payable distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's Days Payable falls into.

Regen BioPharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Regen BioPharma's Days Payable for the fiscal year that ended in Sep. 2023 is calculated as

	Days Payable (A: Sep. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Sep. 2022 )	+	Accounts Payable (A: Sep. 2023 ))	/	count )	/	Cost of Goods Sold (A: Sep. 2023 )	*	Days in Period
=	( (0.029	+	0.03)	/	2 )	/	0	*	365
=	0.0295					/	0	*	365
=	N/A

Regen BioPharma's Days Payable for the quarter that ended in Mar. 2024 is calculated as:

	Days Payable (Q: Mar. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2023 )	+	Accounts Payable (Q: Mar. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
=	( (0.044	+	0.03)	/	2 )	/	0	*	365 / 4
=	0.037					/	0	*	365 / 4
=	N/A

Regen BioPharma Days Payable Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Regen BioPharma (Regen BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBP) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

RGBPP.PFD:USA

Address

4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942

Website

https://www.regenbiopharmainc.com

Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.